Abstract-The aim of the present study was to assess the prognostic value of ECG voltages at baseline and their serial changes during follow-up in a large prospective study with standardized follow-up and strictly defined end points. Patients who were 60 years old or older, with systolic blood pressure of 160 to 219 mm Hg and diastolic pressure Ͻ95 mm Hg, were randomized into the double-blind placebo-controlled Systolic Hypertension in Europe trial. Active treatment consisted of nitrendipine, which could be combined with or replaced by enalapril, hydrochlorothiazide, or both. At the end of the double-blind part of the trial (median follow-up, 2.0 years), follow-up was extended and all patients received active study drugs (median total follow-up, 6.1 years). Electrocardiography was performed at baseline and yearly thereafter. Electrocardiographic left ventricular mass was prospectively defined as the sum of 3 voltages (RaVLϩSV1ϩRV5), which averaged 3.1Ϯ1.0 mV. The adjusted relative hazard rate, associated with a 1 mV higher sum at baseline, amounted to 1.10 and 1.15 for all-cause and cardiovascular mortality and to 1.21 and 1.18 for strokes and cardiac events, respectively (PՅ0.01 for all 
T here is convincing evidence that electrocardiographic (ECG) and echocardiographic (ECHO) left ventricular hypertrophy (LVH) are associated with increased cardiovascular morbidity and mortality, [1] [2] [3] [4] [5] [6] [7] but the independent prognostic implications of LVH regression remain a matter of debate. 8 -14 The possible benefit of LVH regression has been examined in a number of smaller echocardiographic studies in hypertensive patients, 9 -11,13,14 and by use of ECG in subjects with LVH in the Framingham Heart Study 8 and in patients at high cardiovascular risk in the Heart Outcomes Prevention Evaluation (HOPE) trial. 12 It was generally concluded that LVH regression was associated with a reduced risk for cardiovascular events. LVH was analyzed as a categorical variable in these studies, which is of concern for the ECG in view of its low sensitivity for the diagnosis of LVH. Furthermore, relevant changes in left ventricular mass (LVM) or ECG features may occur while still within the limits of LVH. In the present study, we examine the prognostic implications of ECG voltages at baseline and their serial quantitative changes during follow-up, over and above blood pressure (BP) control and other confounding variables, in older patients with systolic hypertension, randomized into the Systolic Hypertension in Europe (Syst-Eur) trial. 15, 16 
Methods

Trial Design
Patients with systolic hypertension, aged 60 years or older, were randomized into the double-blind placebo-controlled Syst-Eur trial, in which active treatment consisted of nitrendipine, with the possible addition of enalapril and/or hydrochlorothiazide (phase 1). 15 When phase 1 of the trial was stopped in February 1997, after a median follow-up of 2.0 years (range, 1 month to 8.1 years), 15 all patients received active study treatment during extended follow-up until December 2001 (phase 2). 16 The placebo group in phase 1 of the trial is termed "control group" in the current report and the actively treated group "active treatment group." The protocol was approved by the Ethics Committees of the University of Leuven and participating centers; patients gave informed consent.
At each follow-up visit, 15, 16 BP was the average of 2 BP measurements in the sitting position, by use of standard sphygmomanometry. Baseline BP was the average of 2 BP at each of 3 visits. A standard 12-lead ECG was performed at baseline and yearly thereafter. As predefined in the protocol, investigators at the coordinating office measured the voltages of SV1, RaVL, and RV5 (mV). ECG LVM was defined as the sum of RaVLϩSV1ϩRV5 17, 18 and ECG-LVH as RaVLϩSV1ϩRV5Ͼ4.7 mV.
All events that occurred during follow-up were corroborated by the Syst-Eur End Point Committee. 15, 16 Outcome variables were: (1) Fatal and nonfatal strokes. Stroke was defined as a neurological deficit with symptoms continuing for Ͼ24 hours or leading to death with no apparent cause other than vascular. (2) Fatal and nonfatal coronary heart disease, comprising acute myocardial infarction and sudden death. Myocardial infarction was defined as 2 of the following 3 disorders: typical chest pain, electrocardiographic changes, and increased cardiac enzymes. Sudden death included any death of unknown origin occurring immediately or within 24 hours of the onset of acute symptoms, as well as unattended death for which no likely cause could be established by necropsy or medical history. Angina pectoris and arrhythmias were not included, unless fatal. (3) Fatal and nonfatal heart failure, irrespective of hospitalization. The diagnosis required the presence of the following 3 disorders or symptoms: (a) dyspnea; (b) clinical signs (such as ankle edema or pulmonary crepitations); and (c) the necessity of treatment with diuretics, vasodilators or antihypertensive drugs. (4) All cardiac events comprise coronary heart disease and heart failure as defined. (5) All cardiovascular events comprise all strokes and all cardiac events as defined. (6) Cardiovascular mortality, including all fatal cardiovascular events. (7) All-cause mortality.
Statistical Analysis
Database management and statistical analysis were performed using SAS software, version 6.12 (SAS Institute Inc). Data are reported as meanϮSD or as proportions. Comparisons between groups were performed by Student unpaired t tests or by 2 tests. The prognostic significance of baseline ECG voltages and ECG LVH was assessed by Cox regression analysis on patients in whom a baseline ECG was available, with exclusion of patients with previous myocardial infarction, left bundle branch block, or implanted artificial pacemaker. The prognostic value of serial changes in ECG voltages during follow-up was analyzed in patients with a baseline ECG and at least 1 follow-up ECG. In a first analysis, the change of ECG voltages from baseline was entered as a time-dependent covariate in Cox regression models. 19 In this analysis, the likelihood of an event that occurred at time "t" depends on the value of the last available ECG before time "t" for all subjects still in follow-up at time "t." In a second analysis, we used the changes in ECG voltages from baseline to the last available ECG, which is the last ECG before the event in case of an event. In the analysis of baseline ECG, we adjusted for age, gender, body mass index, smoking, systolic BP, pulse rate, diabetes, and previous antihypertensive treatment and cardiovascular complications at baseline. 15 In the analysis of ECG changes during follow-up, we also adjusted for baseline ECG voltages and concomitant systolic BP changes. In the combined analysis of the 2 study groups, we also adjusted for study group. In patients with Ͼ1 cardiovascular event, the first relevant event was considered in each of the analyses. Relative hazard rates reflect the risk associated with a 1-mV higher value of RaVLϩSV1ϩRV5 or the presence of LVH at baseline, or a 1-mV decrease in ECG voltages during follow-up. A 2-tailed PՅ0.05 was considered significant.
Results
Patient Characteristics at Baseline
Among the 4695 patients randomized in the Syst-Eur trial, 165 patients had a previous myocardial infarction, 6 a left bundle branch block, 10 an artificial pacemaker, and 7 had missing voltages or calibration signal on the ECG, leaving 4507 patients for the analysis on baseline ECG. Of these 4507 patients, 348 were excluded from the analysis on the follow-up ECG, because of premature death (nϭ52), myocardial infarction (nϭ23) or pacemaker implantation (nϭ2), interruption of regular follow-up (nϭ152), missing/incomplete ECG (nϭ118), or newly developed left bundle branch block (nϭ1). The characteristics of the 4507 and 4159 patients are given in Table 1 and were not significantly different between the active treatment group and the control group.
Prognostic Significance of Baseline ECG Voltages
Median follow-up of the 4507 patients after randomization was 6.1 years (range, 0.1 to 13 years); total follow-up time was 28 743 patient-years. Table 2 summarizes the number of events and the relative hazard rates reflecting the risk associated with a 1-mV greater sum of RaVLϩSV1ϩRV5. In the combined analysis of the 2 treatment groups, ECG voltages significantly and independently predicted total and cardiovascular mortality, all strokes, all cardiac events, coronary heart disease, heart failure, and aggregate fatal and nonfatal cardiovascular events (PՅ0.01). The relative hazard rate for sudden death was significant before ( 
Prognostic Significance of Changes in ECG Voltages During Follow-Up
A total of 22 412 follow-up ECG were recorded in the 4159 patients during the trial. Median follow-up after the first follow-up ECG was 5.1 years (range, 0.003 to 11.8 years) in the active treatment group and 5.1 years (range, 0.003 to 12.0 years) in the control group; total follow-up times were, respectively, 11 863 and 11 316 patient-years. Placebo treatment was gradually replaced by active therapy in the control group as more patients entered phase 2 of the trial. The Figure illustrates the changes in ECG voltages and in BP during follow-up. In multiple regression analysis, after adjustment for baseline ECG voltages, reductions in ECG voltages were more pronounced in the presence of greater decreases in systolic BP (PϽ0.05). Table 3 summarizes the results on the prognostic significance of changes in ECG voltages during follow-up when entered as a time-dependent variable. In both groups taken together, changes in ECG voltages predicted cardiac events independently of baseline ECG voltages and other covariates, including changes in systolic BP. A 1-mV decrease in ECG voltages was associated with a 14% reduction in all cardiac events and a 16% reduction in coronary heart disease risk (PՅ0.05). ECG changes during follow-up did not predict total mortality, cardiovascular mortality, sudden death or the incidence of stroke. In the analysis in which the last available ECG was used, the risk reduction in cardiac events and coronary heart disease amounted to, respectively, 17% and 21% (PՅ0.01) ( Table 4 ).
Discussion
The current study extends the generally accepted prognostic significance of LVH/LVM 1-7 to elderly patients with systolic hypertension, and gives strength to the suggestion that treatment-induced reductions in LVH/LVM have independent prognostic power. 8 -14 In the separate analysis of the 2 treatment groups, the latter finding was significant in the group that received active treatment throughout the trial, but not in the control group in which subjects received placebo during phase 1 of the trial and active therapy during phase 2, after having been in phase 1 for variable periods of time.
There is little doubt that ECHO LVH and ECG LVH are associated with increased incidence of cardiovascular events. 1-7 ECG studies have used a variety of criteria to define LVH, usually including voltage measurements, but it is well known that the ECG has relatively low sensitivity for the detection of LVH. Furthermore, this approach does not consider the full quantitative range of ECG voltages. In the current study, we measured voltages in 3 leads reflecting potentials from the left ventricle. The sum of RaVLϩSV1ϩRV5 predicted all-cause and cardiovascular mortality, stroke, cardiac events, and all cardiovascular events combined. A 1-mV higher value was associated with a 19% greater risk of a cardiovascular event, independent of important confounders including age, gender, and BP.
Whereas the prognostic significance of LVH is well accepted, there is less certainty on the independent prog- Relative hazard rates (95% confidence interval) reflect the risk associated with a 1-mV higher value of RaVLϩSV1ϩRV5. N indicates number of events; CHD, coronary heart disease; HF, heart failure; MI, myocardial infarction; SD, sudden death. *Adjusted relative hazard rates account for age, gender, body mass index, smoking, systolic blood pressure and pulse rate, diabetes, previous antihypertensive treatment, and cardiovascular complications at baseline, and also for study group for the combined analysis of both groups.
N of (first) cause-specific events in each category: †89 With regard to cause-specific cardiovascular disease, we observed that the prognostic value of baseline ECG voltages and changes during follow-up were consistent for coronary heart disease but not for stroke. This could mean that ECG LVM is a marker of overall risk for cardiovascular disease including stroke, but that the favorable effects of LVM regression only pertain to cardiac complications, possibly related to improved cardiac function, coronary flow reserve, and/or less arrhythmias. Another explanation could be that stroke is more powerfully related to BP and changes in BP than are cardiac events. Among previous studies, only Mathew et al 12 reported on specific cardiovascular events and found that regression or prevention of ECG LVH was associated with a lower incidence of cardiac events in comparison with development or persistence of LVH, whereas there was only a nonsignificant trend for stroke.
In the current study, the regression of ECG LVM was achieved with nitrendipine-based antihypertensive therapy to which enalapril and hydrochlorothiazide could be added. Regression of ECHO LVM has been observed with all 3 drug classes. 20 Dihydropyridine calcium channel blockers have been shown to be as effective in reducing LVM as other first-line agents in directly comparative studies. 21, 22 Strengths of the current study are the prospective design, the large sample size, the large number of events allowing cause-specific analyses, the blinded evaluation of the events by an End Point Committee, and the yearly recorded ECG. However, several limitations have to be considered. Because of the 198 centers involved in Eastern and Western Europe and the older study population, echocardiography was not included in the protocol of the trial. The quantitative ECG analysis was limited to the simple measurement of 3 predefined voltages, reflecting the left ventricle, as in the EWPHE trial conducted by the same investigators. 23, 24 In the current study and in previous reports, 17,24 the sum of RaVLϩSV1ϩRV5 was significantly related to systolic BP. In a post hoc analysis of 74 patients from a previous study of our group, 25 in which ECHO LVM was measured in well-standardized conditions, the correlation coefficient of RaVLϩSV1ϩRV5 with ECHO LVM was 0.43, and amounted to 0.46 when LVM was indexed for body surface area (PϽ0.001). Finally, the analysis on the prognostic significance of the follow-up ECG was limited to patients who had at least 1 ECG after randomization.
Perspectives
The current study supports the suggestion that regression of LVH/LVM can be considered a surrogate end point for morbid events in hypertension treatment trials. 26 The relationship of LVH/LVM and of the changes of LVH/ LVM with subsequent morbid events appears to be consistent. In the current study, we found that ECG voltages can be used as a quantitative variable, which is an advantage over categorical analyses, in which patients may remain in the same LVH category despite a relevant change in ECG LVM. Furthermore, electrocardiography is possible in all patients and is less costly and timeconsuming than echocardiography. Whereas there is currently no strong evidence from directly comparative studies, that first-line agents differ in their effects on LVH/ LVM, except perhaps for angiotensin II antagonists, 27 quantitative electrocardiography can probably contribute to the assessment of the effects of newer drugs on LVH/LVM in large study groups. Changes in ECG voltages are entered as time-dependent covariates in the Cox regression models. Relative hazard rates (95% confidence interval) reflect the risk associated with a 1-mV higher sum of SV1ϩRV5ϩRaVL for baseline ECG and the risk associated with a 1-mV decrease in SV1ϩRV5ϩRaVL for delta ECG.
N indicates number of events; CHD, coronary heart disease; HF, heart failure; MI, myocardial infarction; SD, sudden death. *The relative hazard rates for baseline ECG voltages and changes in ECG voltages (delta ECG) are mutually adjusted and also account for age, gender, body mass index, smoking and pulse rate, diabetes, previous antihypertensive treatment, and cardiovascular complications at baseline, baseline systolic BP and changes in systolic BP during follow-up, and also for study group in the combined analysis of both groups.
†PՅ0.05; ‡PՅ0.01; §PՅ0.001. Relative hazard rates (95% confidence interval) reflect the risk associated with a 1 mV higher sum of SV1ϩRV5ϩRaVL for baseline ECG and the risk associated with a 1-mV decrease of SV1ϩRV5ϩRaVL for delta ECG.
*The relative hazard rates for baseline ECG voltages and changes in ECG voltages (delta ECG) are mutually adjusted and also account for age, gender, body mass index, smoking and pulse rate, diabetes, previous antihypertensive treatment and cardiovascular complications at baseline, baseline systolic BP and changes in systolic BP during follow-up, and also for study group in the combined analysis of both groups.
†PՅ0.05; ‡PՅ0.01; §PՅ0.001.
